Uncategorized
Cellceutix developing antibiotic compound for ocular infection
Cellceutix announced that it is currently conducting experiments on brilacidin, an antibiotic compound for the treatment of ophthalmic infections, including keratitis and conjunctivitis, according to a press release.Prior studies have demonstrated the safety, tolerability and broad activity of brilacidin against gram-positive and gram-negative pathogens, including drug-sensitive and drug-resistant clinical isolate strains of ocular infections.